Bee Venom-Derived Lytic Peptide Selectively Kills Cancer Cells Expressing FSH Receptors
A conjugate of the lytic peptide Hecate (bee venom analog) with FSH fragments selectively destroys cancer cells that express FSH receptors while sparing receptor-negative cells.
Quick Facts
What This Study Found
Hecate-FSH beta 33-53 C/S conjugate selectively killed FSHR-positive cancer cells (KGN granulosa tumor cells and FSHR-transfected HEK293 cells) while showing minimal toxicity to FSHR-negative controls.
Key Numbers
Tested in KGN granulosa tumor cells, HEK293-FSHR cells, and FSHR-negative controls; C/S variant showed highest specific cytotoxicity.
How They Did This
In vitro cytotoxicity testing of Hecate-FSH beta conjugate variants in FSHR-positive (KGN, HEK293-FSHR) and FSHR-negative (mock-transfected HEK293) cell lines.
Why This Research Matters
Selective cancer cell killing without harming normal tissue is the holy grail of cancer therapy; this peptide conjugate achieves receptor-targeted cytotoxicity using a nature-derived lytic peptide.
The Bigger Picture
Peptide-based targeted cancer therapies are gaining traction as alternatives to antibody-drug conjugates, offering advantages in size, tissue penetration, and manufacturing simplicity.
What This Study Doesn't Tell Us
In vitro study only — in vivo tumor targeting, biodistribution, stability, and safety not yet assessed; FSHR expression varies across tumor types and patients.
Questions This Raises
- ?Can this Hecate-FSH beta conjugate effectively target FSHR-positive tumors in vivo without off-target toxicity to ovarian tissue?
- ?Could this approach be combined with other peptide-drug conjugate strategies for enhanced efficacy?
Trust & Context
- Key Stat:
- Selective kill Hecate-FSH beta conjugate destroyed FSHR-positive cancer cells while sparing FSHR-negative cells
- Evidence Grade:
- In vitro proof-of-concept study; demonstrates selectivity but animal and human studies are needed.
- Study Age:
- Published in 2025, contributing to the growing field of targeted lytic peptide cancer therapeutics.
- Original Title:
- Hecate-FSHβ33-53C/S lytic peptide conjugate selectively kills targeted follicle stimulating hormone receptor (FSHR)-positive cancer cells.
- Published In:
- Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 186, 118022 (2025)
- Authors:
- Rahman, Nafis A, Chrusciel, Marcin, Ponikwicka-Tyszko, Donata, Pulawska-Moon, Kamila, Stelmaszewska, Joanna, Doroszko, Milena, Kreuzer, Oliver J, Rivero-Muller, Adolfo, Li, Xiangdong, Ziecik, Adam J, Wolczynski, Slawomir, Huhtaniemi, Ilpo
- Database ID:
- RPEP-13171
Evidence Hierarchy
Frequently Asked Questions
How does this peptide target cancer cells?
The Hecate lytic peptide is attached to a fragment of follicle-stimulating hormone (FSH) that acts as a homing signal. Cancer cells with FSH receptors on their surface bind the FSH fragment, allowing the lytic peptide to destroy them while ignoring cells without the receptor.
What types of cancer express FSH receptors?
FSH receptors are found on ovarian cancers, prostate cancers, and the blood vessel cells that feed tumors. This makes FSHR a useful target for selective cancer therapies that spare normal tissue.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-13171APA
Rahman, Nafis A; Chrusciel, Marcin; Ponikwicka-Tyszko, Donata; Pulawska-Moon, Kamila; Stelmaszewska, Joanna; Doroszko, Milena; Kreuzer, Oliver J; Rivero-Muller, Adolfo; Li, Xiangdong; Ziecik, Adam J; Wolczynski, Slawomir; Huhtaniemi, Ilpo. (2025). Hecate-FSHβ33-53C/S lytic peptide conjugate selectively kills targeted follicle stimulating hormone receptor (FSHR)-positive cancer cells.. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 186, 118022. https://doi.org/10.1016/j.biopha.2025.118022
MLA
Rahman, Nafis A, et al. "Hecate-FSHβ33-53C/S lytic peptide conjugate selectively kills targeted follicle stimulating hormone receptor (FSHR)-positive cancer cells.." Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2025. https://doi.org/10.1016/j.biopha.2025.118022
RethinkPeptides
RethinkPeptides Research Database. "Hecate-FSHβ33-53C/S lytic peptide conjugate selectively kill..." RPEP-13171. Retrieved from https://rethinkpeptides.com/research/rahman-2025-hecatefsh3353cs-lytic-peptide-conjugate
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.